Viatris' Mylan Recalls One Lot Of Octreotide Acetate Injection Due To Glass Particulates

  • Viatris Inc's VTRS Mylan is voluntarily recalling one lot of Octreotide Acetate Injection, 500 mcg/mL, packaged in a carton of ten 1mL syringes due to a product complaint of the presence of glass particles in a syringe.
  • The lot was manufactured by Italfarmaco SpA, Italy, and was distributed by Mylan Institutional LLC in the U.S. between January 11 and June 21, 2022.
  • Also read: Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label.
  • Octreotide Acetate Injection is indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients. 
  • It is also indicated for the symptomatic treatment of patients with metastatic carcinoid tumors, where it suppresses or inhibits severe diarrhea and flushing episodes.
  • Intravenous administration of a solution containing particulate matter could lead to events including local irritation or swelling, vasculitis/phlebitis, allergy, and microvascular obstruction. 
  • No reports of adverse reactions associated with this lot have been received to date.
  • Price Action: VTRS shares are up 1.89% at $9.97 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!